Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products.
Talarico R, Ramirez GA, Barreira SC, Cardamone C, Triggianese P, Aguilera S, Andersen J, Avcin T, Benistan K, Bertsias G, Bortoluzzi A, Bouillot C, Bulina I, Burmester GR, Callens S, Carreira PE, Cervera R, Cutolo M, Damian L, Della-Torre E, Faria R, Fonseca JE, Galetti I, Hachulla E, Iaccarino L, Jacobsen S, Khmelinskii N, Limper M, Marinello D, Meyer A, Moroncini G, Nagy G, Olesinska M, Pamfil C, Pileckyte M, Pistello M, Rednic S, Richez C, Romão VC, Schneider M, Sciascia S, Scirè CA, Simonini G, Smith V, Sulli A, Tani C, Tas SW, Tincani A, Vonk MC, Tektonidou M, Mosca M. Talarico R, et al. Among authors: richez c. Clin Exp Rheumatol. 2023 Mar;41(3):543-553. doi: 10.55563/clinexprheumatol/jpargp. Epub 2023 Mar 14. Clin Exp Rheumatol. 2023. PMID: 36916322 Free article.
COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection.
Comarmond C, Drumez E, Labreuche J, Hachulla E, Thomas T, Flipo RM, Seror R, Avouac J, Balandraud N, Desbarbieux R, Felten R, Gilson M, Guyot MH, Hittinger-Roux A, Pham T, Renard M, Roux N, Sobanski V, Tournadre A, Richez C, Cacoub P; FAI2 R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Comarmond C, et al. Among authors: richez c. J Transl Autoimmun. 2023 Jan 14;6:100190. doi: 10.1016/j.jtauto.2023.100190. eCollection 2023. J Transl Autoimmun. 2023. PMID: 36684808 Free PMC article.
Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry.
Yazdany J, Ware A, Wallace ZS, Bhana S, Grainger R, Hachulla E, Richez C, Cacoub P, Hausmann JS, Liew JW, Sirotich E, Jacobsohn L, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schaefer M, Ribeiro SLE, Al-Emadi S, Hasseli R, Müller-Ladner U, Specker C, Schulze-Koops H, Bernardes M, Fraga VM, Rodrigues AM, Sparks JA, Ljung L, Di Giuseppe D, Tidblad L, Wise L, Duarte-García A, Ugarte-Gil MF, Colunga-Pedraza IJ, Martínez-Martínez MU, Alpizar-Rodriguez D, Xavier RM, Isnardi CA, Pera M, Pons-Estel G, Izadi Z, Gianfrancesco MA, Carrara G, Scirè CA, Zanetti A, Machado PM. Yazdany J, et al. Among authors: richez c. Arthritis Care Res (Hoboken). 2024 Feb;76(2):274-287. doi: 10.1002/acr.25220. Epub 2023 Nov 7. Arthritis Care Res (Hoboken). 2024. PMID: 37643903
CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases.
Chevalier K, Genin M, Jean TP, Avouac J, Flipo RM, Georgin-Lavialle S, El Mahou S, Pertuiset E, Pham T, Servettaz A, Marotte H, Domont F, Chazerain P, Devaux M, Mekinian A, Sellam J, Fautrel B, Rouzaud D, Ebstein E, Costedoat-Chalumeau N, Richez C, Hachulla E, Mariette X, Seror R. Chevalier K, et al. Among authors: richez c. Front Med (Lausanne). 2023 Mar 22;10:1152587. doi: 10.3389/fmed.2023.1152587. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37035330 Free PMC article.
Comparing COVID-19 disease severity in patients with rheumatic and inflammatory diseases between the first and the subsequent waves.
Drumez E, Richez C, Bebear L, Herasse M, Flipo RM, Marotte H, Georgin-Lavialle S, Seror R, Pertuiset E, Avouac J, Chazerain P, Roux N, Pham T, Dernis E, Uzunhan Y, Servettaz A, El Mahou S, Cacoub P, Hamidou M, Fautrel B, Thomas T, Hachulla E; Consortium; contributors. Drumez E, et al. Among authors: richez c. Joint Bone Spine. 2023 Sep;90(5):105605. doi: 10.1016/j.jbspin.2023.105605. Epub 2023 Jul 1. Joint Bone Spine. 2023. PMID: 37399939 No abstract available.
Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry.
Faganello D, Bertrand A, Meunier P, Avouac J, Toussirot E, Coury F, Seror R, Le Mélédo G, Germain V, Dellal A, Shima D, Hulin C, Prati C, Schaeverbeke T, Richez C, Truchetet ME, Kostine M. Faganello D, et al. Among authors: richez c. Rheumatology (Oxford). 2024 Mar 1;63(3):787-790. doi: 10.1093/rheumatology/kead187. Rheumatology (Oxford). 2024. PMID: 37540112
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study.
de Frémont GM, Costedoat-Chalumeau N, Lazaro E, Belkhir R, Guettrot-Imbert G, Morel N, Nocturne G, Molto A, Goulenok T, Diot E, Perard L, Ferreira-Maldent N, Le Besnerais M, Limal N, Martis N, Abisror N, Debouverie O, Richez C, Sobanski V, Maurier F, Sauvetre G, Levesque H, Timsit MA, Tieulié N, Orquevaux P, Bienvenu B, Mahevas M, Papo T, Lartigau-Roussin C, Chauvet E, Berthoux E, Sarrot-Reynauld F, Raffray L, Couderc M, Silva NM, Jourde-Chiche N, Belhomme N, Thomas T, Poindron V, Queyrel-Moranne V, Delforge J, Le Ray C, Pannier E, Mariette X, Le Guern V, Seror R; GR2 Study Group. de Frémont GM, et al. Among authors: richez c. Lancet Rheumatol. 2023 Jun;5(6):e330-e340. doi: 10.1016/S2665-9913(23)00099-1. Epub 2023 May 8. Lancet Rheumatol. 2023. PMID: 38251600
206 results